Magazine Article | October 1, 2020

PPA Differences Between Small And Large Sponsors

Source: Life Science Leader

By Industry Standard Research

The overwhelming majority of respondents (85%) at small and emerging biopharma companies do not have preferred provider agreements (PPAs) for Phase 2/3 outsourcing. This is a striking comparison to the wider audience of clinical development outsourcers — 83 percent of large sponsors and 47 percent of midsize sponsors said they have PPAs in place. What does this mean? With only about one-in-10 respondents bound by PPAs, it is a CRO’s market.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: